Literature DB >> 12651877

Pharmacogenomics: marshalling the human genome to individualise drug therapy.

W E Evans1.   

Abstract

Pharmacogenomics aims to identify the inherited basis for interindividual differences in drug response, and translate this to molecular diagnostics that can be used to individualise drug therapy. This review uses a number of published examples of inherited differences in drug metabolising enzymes, drug transporters, and drug targets (for example, receptors) to illustrate the potential importance of inheritance in determining the efficacy and toxicity of medications in humans. It seems that this field is at the early stages of developing a powerful set of molecular diagnostics that will have profound utility in optimising drug therapy for individual patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651877      PMCID: PMC1867751          DOI: 10.1136/gut.52.suppl_2.ii10

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  139 in total

1.  Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics.

Authors:  S Tan; I P Hall; J Dewar; E Dow; B Lipworth
Journal:  Lancet       Date:  1997-10-04       Impact factor: 79.321

2.  Human acetyltransferase polymorphisms.

Authors:  D M Grant; N C Hughes; S A Janezic; G H Goodfellow; H J Chen; A Gaedigk; V L Yu; R Grewal
Journal:  Mutat Res       Date:  1997-05-12       Impact factor: 2.433

3.  Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia.

Authors:  S M Davies; L L Robison; J D Buckley; T Tjoa; W G Woods; G A Radloff; J A Ross; J P Perentesis
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

5.  Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study.

Authors:  M Stanulla; M Schrappe; A M Brechlin; M Zimmermann; K Welte
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

6.  Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia.

Authors:  R Kaiser; M Könneker; M Henneken; M Dettling; B Müller-Oerlinghausen; I Roots; J Brockmöller
Journal:  Mol Psychiatry       Date:  2000-07       Impact factor: 15.992

7.  Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms.

Authors:  D Otterness; C Szumlanski; L Lennard; B Klemetsdal; J Aarbakke; J O Park-Hah; H Iven; K Schmiegelow; E Branum; J O'Brien; R Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  1997-07       Impact factor: 6.875

Review 8.  Pharmacogenomics: the inherited basis for interindividual differences in drug response.

Authors:  W E Evans; J A Johnson
Journal:  Annu Rev Genomics Hum Genet       Date:  2001       Impact factor: 8.929

9.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

Review 10.  The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics.

Authors:  J Seidegård; G Ekström
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

View more
  18 in total

1.  Drug metabolism and pharmacogenetics: the British contribution to fields of international significance.

Authors:  John Caldwell
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

2.  Genetic polymorphism of CYP2C19 in Maharashtrian population.

Authors:  Yogita Ghodke; Kalpana Joshi; Yashendra Arya; Anjali Radkar; Aditi Chiplunkar; Pooja Shintre; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

3.  Predictors of 12-month outcome in smokers who received bupropion sustained-release for smoking cessation.

Authors:  Gary E Swan; Lisa M Jack; Harold S Javitz; Tim McAfee; Jennifer B McClure
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China.

Authors:  Yuanwei Liu; Haiyue Li; Keqing Cao; Jianfeng Liu; Yao Sun; Jiamin Wu; Zichao Xiong; Fanglin Niu; Jing Li; Tianbo Jin
Journal:  Pharmacogenomics J       Date:  2020-07-23       Impact factor: 3.550

Review 5.  Implementing Precision Medicine: The Ethical Challenges.

Authors:  Diane M Korngiebel; Kenneth E Thummel; Wylie Burke
Journal:  Trends Pharmacol Sci       Date:  2016-12-07       Impact factor: 14.819

6.  Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.

Authors:  Paraskevi F Katsakiori; Eirini P Papapetrou; George C Sakellaropoulos; Dimitrios S Goumenos; George C Nikiforidis; Christodoulos S Flordellis
Journal:  Int J Med Sci       Date:  2010-05-11       Impact factor: 3.738

Review 7.  Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.

Authors:  Lucy Gossage; Srinivasan Madhusudan
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

8.  New pathways for alimentary mucositis.

Authors:  Joanne M Bowen; Dorothy M K Keefe
Journal:  J Oncol       Date:  2008-09-23       Impact factor: 4.375

9.  Role of pharmacogenomics in the treatment of tuberculosis: a review.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Pharmgenomics Pers Med       Date:  2012-09-13

10.  Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability.

Authors:  Yogita Ghodke; Kalpana Joshi; Bhushan Patwardhan
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.